Highlights

Roth Capital Starts Coverage on AEterna Zentaris (AEZS)

 Source: ABMN Staff   |   Publish date: Thu, 20 Sep 08:04   |    >> Read article in News website

Research analysts at Roth Capital began coverage on shares of AEterna Zentaris (NASDAQ: AEZS) in a report released on Thursday. The firm set a “buy” rating on the stock.

AEterna Zentaris opened at 0.6801 on Thursday. AEterna Zentaris has a 1-year low of $0.38 and a 1-year high of $2.17. The company’s market cap is $76.4 million.

A number of other firms have also recently commented on AEZS. Analysts at Oppenheimer reiterated a “perform” rating on shares of AEterna Zentaris in a research note to investors on Thursday, August 16th. Analysts at RBC Capital cut their price target on shares of AEterna Zentaris from $0.70 to $0.55 in a research note to investors on Thursday, August 16th. They now have a “sector perform” rating on the stock.

Aeterna Zentaris Inc. (Aeterna Zentaris) is a drug development company specialized in oncology and endocrine therapy.

Share this

  Be the first to like this.
 


 

4180  2954  630  398 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 SPY 196.43+1.50 
 F 13.78-0.62 
 DRYS 1.52-0.48 
 PBR 12.93+0.82 
 VXX 33.17-0.31 
 MSFT 46.13+1.11 
 EWZ 41.57+1.73 
 AAPL 105.22+0.39 
 EEM 41.02+0.29 
 QQQ 98.62+0.80 
Partners & Brokers